Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02790047
Other study ID # PHD/0082/2556
Secondary ID
Status Recruiting
Phase N/A
First received February 2, 2016
Last updated October 27, 2016
Start date October 2016
Est. completion date May 2018

Study information

Verified date October 2016
Source Khon Kaen University
Contact Chatchai Phimphasak, M.Sc., PT
Phone +66861779571
Email chatmomo_chai@hotmail.com
Is FDA regulated No
Health authority Thailand: Khon Kaen University Ethics Committee for Human Research
Study type Interventional

Clinical Trial Summary

The aim of this study to investigate the efficacy of a home-base exercise program with a new conical PEP device on physical performance and health related quality of life in COPD patients.


Description:

The key pathophysiology of COPD is expiratory flow limit and hyperinflation that is a major factor related exertional dyspnea and exercise limitation. When expiratory minute volume( V ̇E) raise up while exercise, respiratory response by increase respiratory rate (RR) and tidal volume (VT), force exhalation occur lead to develop premature airway closer. These generate dynamic air tapping breath by breath and result in dynamic hyperinflation (DH). The DH limits VT expansion, increase respiratory muscle load, and it is a major cause related dyspnea and exercise termination. Furthermore, Pre-inflammatory products from the COPD lung contribute to another system, and provoke systemic inflammation lead to nutritional abnormalities, weight loss, skeletal muscle dysfunction, osteo-skeletal effect, cardiovascular effect and psychological effect. All of these affect the exercise tolerance and gradually affect physical activity and health-related quality of life (HRQL) as well.

COPD GOLD guideline states that goal for treatments of stable COPD comprise of relive symptoms, improve exercise tolerance, improve health status, prevent disease progression and reduce mortality. Several evidences have suggested an effect of pulmonary rehabilitation (PR) in patient with stable COPD and following acute exacerbation. Strong evidences reported that the PR program could improve exercise tolerance, reduce dyspnea, decrease fatigue and improve health-related quality of life.

The core stone of PR is an exercise program. Several types of exercise were published such as endurance exercise, interval exercise, strengthening exercise, respiratory muscle strengthening and breathing exercise. Most COPD patient stop exercise causes from dyspnea that related DH development during exercise. Previous studies reported various strategies to reduce DH development during exercise for extending exercise time or increase exercise capacity in immediate effect such as bronchodilators , hyperoxic breathing, heliox breathing, positive pressure therapy by non-invasive positive pressure ventilation (NIPPV), by pursed lip breathing (PLB) and by positive expiratory pressure (PEP) device.

The PEP therapy have been conventionally using for reduce premature airway closer by moving equal pressure point from distal to proximal, improve gas exchange and improve secretion clearance. In the past decade, the knowledge of dynamic hyperinflation in COPD patient has rapidly glowed up. The PEP device and PLB have used to reduce DH development during exercise that reported in only 5 studies. They expected that delay DH development, it may delay exertional dyspnea, and may result in improve exercise capacity.

Three studies reported DH parameter at pre and post exercise. Results indicated that using the PEP device can reduce DH when measuring immediate post exercise. However, effects of positive pressure therapy (PEP device and PLB) on exercise capacity were also inconclusive. But three studies showed positive effect of PEP therapy on exercise capacity.

Training effect of PEP therapy on physical performance and quality of life was present in two studies. The first study showed the benefit of breathing retraining (including PLB, and other breathing techniques) that were integrated to all daily activities and exercise program, superior than control group in peak oxygen consumption after 7th week of exercise program. The second study applied PLB to reduce DH during exercise program. They found that after ten sessions (within 3 to 4 weeks) of program, both PLB and control groups significantly improve 6 minute walk distance and quality of life, but non-significant effect between groups. To date there was only two studies of PEP therapy applying to exercise program, and results were not conclusive.

In spite of the PLB was wildly used, but positive pressure from this technique was reported about 5 cm H2O, it is lower boundary of therapeutic pressure range (5 to 20 cm H2O), this may result in a non-success of DH reduction. Consequently, The PEP device may be a convenient alternative way to generate positive pressure within therapeutic range for reduces DH during exercise or daily activities living. This may increase patient's physical performance and quality of life greater that exercise alone.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date May 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender Both
Age group 35 Years to 80 Years
Eligibility Inclusion Criteria:

- COPD patients (with FEV1 =70% predicted)

Exclusion Criteria:

- Exacerbate within a month prior, which was a cause of admission to the hospital emergency room or been admitted to hospital.

- Are changed medicines within a month ago.

- Have been used home oxygen therapy.

- Have musculoskeletal or neuromuscular problem affecting balance and walking. and spot marching exercise.

- Using walking aid device.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
A non-re-breathing face mask with conical-PEP device
Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
Other:
A home-base exercise program
Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale < 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol. Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes
Health education
Health education include Knowledge of COPD disease Smoking status and smoking cessation Medication correctly Self dyspnea management Basic nutrition for COPD
?Breathing strategies for self secretion clearance
Using a modified active cycle breathing technique (mACBT) include Control breathing Pursed lip breathing (PLB) Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique Force expiratory technique (FET) with low to medium lung volume Huffing or coughing
Drug:
The medication following the COPD GOLD guidelines (2015)
Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral) Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler) Xanthine derivative (sustained release theophylline) Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler) Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler) Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler) Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)

Locations

Country Name City State
Thailand School of Physical Therapy, Faculty of Associated Medical Sciences Muang Khon Kaen Khon Kaen
Thailand Srinagarind Hospital Muang Khon Kaen Khon Kaen

Sponsors (2)

Lead Sponsor Collaborator
Khon Kaen University The Thailand Research Fund

Country where clinical trial is conducted

Thailand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of 6 minute walk distance (6MWD) The 6MWD represents physical performance of COPD pateints. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of St George's Respiratory Questionnaire (SGRQ) score The SGRQ represents health related quality of life of COPD patients. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Incremental sport marching exercise test (ISMT) The ISMT is combination movement of high arm and leg raising on the spot . Patient will start ISMT with 60 or 70 steps/minute and increase 10 to 20 steps/minute every 2 minutes until symptom limited. Aim of this test is to fine maximum step rate and step rate which patient perceive at least moderate dyspnea or breathlessness. The proper step rate will use in endurance spot marching exercise test (ESMT). baseline No
Secondary Change of endurance exercise time of endurance sport marching exercise test (ESMT) The ESMT is a physical performance parameter. The exercise capacity of this test is endurance exercise time. Patents will perform ESMT with constant step rate until symptom limit or exercise time up to 25 minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting inspiratory capacity (IC) The resting IC reflects static hyperinflation. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise inspiratory capacity in ESMT (IC-ESMT) The end exercise IC reflects dynamic hyperinflation. patient will be measured the end exercise IC at immediate post ESMT. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting slow vital capacity (SVC) The resting SVC reflect static hyperinflation baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise slow vital capacity in ESMT (SVC-ESMT) The resting SVC reflect dynamic hyperinflation.patient will be measured the end exercise IC at immediate post ESMT. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting heart rate (HR) Patients will be measured resting EKG for 20 minutes. the EKG will be analysis to resting HR baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting respiratory rate (RR) Patients will be measured resting RR for 20 minutes. The RR will be recorded every minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting pulse oxygen saturation (SpO2) Patients will be measured resting SpO2 for 20 minutes. The SpO2 will be recorded every minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting end tidal carbon dioxide (PetCO2) Patients will be measured resting PetCO2 for 20 minutes. The PetCO2 will be recorded every minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting systolic blood pressure (SBP) Patients will be measured resting SBP every 2 minutes for 20 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting diastolic blood pressure (DBP) Patients will be measured resting DBP every 2 minutes for 20 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting mean arterial pressure (MAP) Patients will be measured resting MAP every 2 minutes for 20 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting pusle wave velocity (PWV) Patients will be continuously measured resting EKG and photoplethysmography (PPG) for 20 minutes. The pulse transit time will be collected from EKG and PPG, then the pulse transit time in each patient will divide by a length of their arm (from jugular notch to tip of index finger ) baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise heart rate in ESMT (HR-ESMT) Patients will be continuously measured EKG during ESMT. The investigators will collect end exercise HR at immediate post ESMT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise rating perceive of breathlessness in ESMT (RPB-ESMT) Patients will rate their breathlessness using 10 scale of modified Borg dyspnea scale at pre-ESMT, during ESMT every minute, end ESMT and every minute in recovery period for 10 minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise respiratory rate in ESMT (RR-ESMT) Patients will be recorded RR at pre-ESMT, during ESMT every minute, end ESMT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise tidal volume in ESMT (RR-ESMT) Patients will be recorded tidal volume at pre-ESMT, end ESMT and end recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise minute ventilation in ESMT (RR-ESMT) Patients will be recorded minute ventilation at pre-ESMT, end ESMT and end recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise pulse oxygen saturation in ESMT (SpO2-ESMT) Patients will be recorded SpO2 at pre-ESMT, during ESMT every minute, end ESMT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise end tidal carbon dioxide in ESMT (PetCO2-ESMT) Patients will be recorded PetCO2 at pre-ESMT, during ESMT every minute, end ESMT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise systolic blood pressure in ESMT (SBP-ESMT) Patients will be recorded SBP at pre-ESMT, immediate end ESMT and every 2 minutes in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise diastolic blood pressure in ESMT (DBP-ESMT) Patients will be recorded DBP at pre-ESMT, immediate end ESMT and every 2 minutes in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise mean arterial pressure in ESMT (MAP-ESMT) Patients will be recorded MAP at pre-ESMT, immediate end ESMT and every 2 minutes in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise pulse wave velocity in ESMT (PWV-ESMT) Patients will be continuously measured EKG and photoplethysmography (PPG) at pre ESMT during ESMT and recovery period for 10 minutes. The pulse transit time will be collected from EKG and PPG at end of ESMT, then the pulse transit time in each patient will divide by a length of their arm (from jugular notch to tip of index finger ) baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise leg fatigue score in ESMT (LEG-ESMT) Patients will rate their leg fatigue using 10 scale of modified Borg leg fatigue scale at pre-ESMT, during ESMT every minute, end ESMT and every minute in recovery period for 10 minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise heart rate in 6MWT (HR-6MWT) Patients will be continuously measured HR during 6MWT. The investigators will collect end exercise HR at immediate post 6MWT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise rating perceive of breathlessness in 6MWT (RPB-6MWT) Patients will rate their breathlessness using 10 scale of modified Borg dyspnea scale at pre-6MWT, during 6MWT every minute, end 6MWT and every minute in recovery period for 10 minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise respiratory rate in 6MWT (RR-6MWT) Patients will be recorded RR at pre-6MWT, during 6MWT every minute, end 6MWT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise pulse oxygen saturation in 6MWT (SpO2-6MWT) Patients will be recorded SpO2 at pre-6MWT, during 6MWT every minute, end 6MWT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise end tidal carbon dioxide in 6MWT (PetCO2-6MWT) Patients will be recorded PetCO2 at pre-6MWT, during 6MWT every minute, end 6MWT and every minute in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise systolic blood pressure in 6MWT (SBP-6MWT) Patients will be recorded SBP at pre-6MWT, immediate end 6MWT and every 2 minutes in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise diastolic blood pressure in 6MWT (DBP-6MWT) Patients will be recorded DBP at pre-6MWT, immediate end 6MWT and every 2 minutes in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise mean arterial pressure in 6MWT (MAP-6MWT) Patients will be recorded MAP at pre-6MWT, immediate end 6MWT and every 2 minutes in recovery period for 10 minutes. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of end exercise leg fatigue score in 6MWT (LEG-6MWT) Patients will rate their leg fatigue using 10 scale of modified Borg leg fatigue scale at pre-6MWT, during 6MWT every minute, end 6MWT and every minute in recovery period for 10 minute. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of resting heart rate variability (HRV) Patients will be measured resting EKG for 20 minutes. The EKG will be analysis to HRV baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of Chronic Obstructive Pulmonary Disease Assessment Test (CAT) score The CAT is health related quality of life questionnaire. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of Modified Medical Research Council Questionnaire (mMRC) score The mMRC is one of dyspnea parameters. It is ordinal data. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of hand grip force The hand grip force represents general health status of patients. patient will be assessed both dominated and non-dominated hands. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of force vital capacity (FVC) and force vital capacity %predicted patient will perform spirometry in FVC maneuver to record post bronco-dilator force vital capacity following American Thoracic Society (ATS) /European Respiratory Society (ERS) statement for spirometry (2005). baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of force expiratory volume in one second (FEV1) and FEV1%predicted patient will perform spirometry in FVC maneuver to record post bronco-dilator FEV1 following ATS/ERS statement for spirometry (2005). baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of FEV1/FVC ratio patient will perform spirometry in FVC maneuver to record post bronco-dilator FEV1/FVC ratio following ATS/ERS statement for spirometry (2005). baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of peak expiratory flow rate (PEF) and PEF%predicted patient will perform spirometry in FVC maneuver to record post bronco-dilator PEF following ATS/ERS statement for spirometry (2005). baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of Maximum inspiratory pressure (MIP) Patients will maximum inhale as fast as possible from functional residual capacity (FRC) to total lung capacity (TLC). baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of Maximum expiratory pressure (MEP) Patients will maximum exhale as fast as possible from TLC to residual volume (RV). baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of Baseline Dyspnea Index (BDI) The BDI is one of dyspnea parameters (questionnaire). Three dimension questions include; 1.effect of daily function on dyspnea, 2. effect of magnitude of task on dyspnea and 3. effect of magnitude off effort on dyspnea. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of Transition Dyspnea Index (TDI) The TDI assesses change of dyspnea perception from the BDI in each dimensions. Patient will rate score from -6 to +6 (positive score reflect improve of dyspnea and negative score reflect worse dyspnea). post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of number of step per day The number of step per day represents physical activity using a pedometer. Patient will contact the pedometer from early wake up to go to bed with 10 day hours for 14 day before starting the home-base exercise program, post the home-base exercise program and 5th months . The researcher will record the regular step per day for 7 days to analysis. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Change of rate of using short acting bronco-dilator per week Patient will be collected the rate of using short acting bronco-dilator per week as 2 months ago of the time frame. baseline, post home-base exercise program at 8th weeks and follow up at 5th months No
Secondary Number of exacerbation event Definition of exacerbation is a cause of admission to the hospital emergency room or admitting to hospital. Collecting from starting the homes-base exercise program to 5th months follow up. No
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy